EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Immune checkpoint inhibitor‐induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma

Yuki Hayakawa, Takako Kawaguchi iD, Kei Yamasaki iD, Miyu Endo, Masaya Komatsu, Yutaka Ishiguro, Yuichi Murata, Kazuhiro Yatera

Respirology Case Reports · 2023-10 · 11 (10)

DOI: 10.1002/rcr2.1222 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Respirology Case Reports, online erschienen am 19.09.2023. Verfasst von Yuki Hayakawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine University of Occupational and Environmental Health, Japan Kitakyushu Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 67‐year‐old current smoker Japanese man, with no history of asthma, was diagnosed with lung adenocarcinoma. He received first‐line chemotherapy with carboplatin, pemetrexed, ipilimumab, and nivolumab in July 20XX‐1, and subsequently a maintenance therapy with nivolumab. In October 20XX, he became aware of wheezy dyspnoea, and chest computed tomography demonstrated worsening bronchial wall thickenings. Eosinophilia was noted, and a pulmonary function test showed obstructive dysfunction insufficiently responding to beta‐agonists, with 130 mL increase of forced expiratory volume in one second and high fractional exhaled nitric oxide level (85 ppb). He was clinically diagnosed with asthma and chronic obstructive pulmonary disease overlap, secondary to immune checkpoint inhibitors (ICIs). The inhibition of binding between programmed cell death‐protein‐1 (PD‐1), expressed on T cells, and programmed cell death‐ligand‐2 (PD‐L2), expressed on tumour and dendritic cells, can induce airway hyperresponsiveness. Physicians should be wary of asthmatic symptoms and chest image findings during ICIs therapy.

Schlagwörter

Stichwörter der Autor:innen

adenocarcinomaasthmachronic obstructive pulmonary diseaseimmune checkpoint inhibitors

Autor:innen und Institutionen

  • Department of Respiratory Medicine University of Occupational and Environmental Health, Japan Kitakyushu Japan.

ORCID-Profile: Takako Kawaguchi, Kei Yamasaki

Zitieren

APA

Hayakawa, Y., Kawaguchi, T., Yamasaki, K., Endo, M., Komatsu, M., Ishiguro, Y., Murata, Y., & Yatera, K. (2023). Immune checkpoint inhibitor‐induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma. Respirology Case Reports, 11(10). https://doi.org/10.1002/rcr2.1222

Vancouver

Hayakawa Y, Kawaguchi T, Yamasaki K, Endo M, Komatsu M, Ishiguro Y, et al. Immune checkpoint inhibitor‐induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma. Respirology Case Reports. 2023;11(10). doi:10.1002/rcr2.1222

BibTeX
@article{Hayakawa2023,
  author = {Hayakawa, Yuki and Kawaguchi, Takako and Yamasaki, Kei and Endo, Miyu and Komatsu, Masaya and Ishiguro, Yutaka and Murata, Yuichi and Yatera, Kazuhiro},
  title = {Immune checkpoint inhibitor‐induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma},
  journal = {Respirology Case Reports},
  year = {2023},
  volume = {11},
  number = {10},
  doi = {10.1002/rcr2.1222}
}
Kostenlos starten →